Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment

References

• Nakase H, Sato N, Mizuno N, et al. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev. 2022;21(3):103017.
   PubMed Web of Science ®Google Scholar
• Grossberg LB, Papamichael K, Cheifetz AS. Review article: emerging drug therapies in inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55(7):789–804.
   PubMed Web of Science ®Google Scholar
• Salas A, Hernandez-Rocha C, Duijvestein M, et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(6):323–337.
   PubMed Web of Science ®Google Scholar
• Wilks AF. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc Natl Acad Sci USA. 1989;86(5):1603–1607.
   PubMed Web of Science ®Google Scholar
• Leonard WJ, O'Shea JJ. JAKS and STATS: biological implications. Annu Rev Immunol. 1998;16(1):293–322.
   PubMedGoogle Scholar
• Tanaka Y, Luo Y, O’Shea JJ, et al. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133–145.
   PubMed Web of Science ®Google Scholar
• Villarino AV, Kanno Y, O'Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–384.
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Meraz MA, White J, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the jaks in cytokine-induced biologic responses. Cell. 1998;93(3):373–383.
   PubMed Web of Science ®Google Scholar
• Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93(3):385–395.
   PubMed Web of Science ®Google Scholar
• Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature. 1995;377(6544):65–68.
   PubMed Web of Science ®Google Scholar
• Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science. 1995;270(5237):797–800.
   PubMed Web of Science ®Google Scholar
• Danese S, Grisham M, Hodge J, et al. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016;310(3):G155–G162.
   PubMed Web of Science ®Google Scholar
• Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40(8):955–962.
   PubMed Web of Science ®Google Scholar
• Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119–124.
   PubMed Web of Science ®Google Scholar
• Liu QF, Li Y, Zhao QH, et al. Association of STAT4 rs7574865 polymorphism with susceptibility to inflammatory bowel disease: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2015;39(5):627–636.
   PubMed Web of Science ®Google Scholar
• Lian LH, Lau TP, Lee VL, et al. Lack of association between TYK2 and STAT3 genes and Crohn’s disease in the Malaysian population. Genet Mol Res. 2013;12(1):167–174.
   PubMed Web of Science ®Google Scholar
• Sato K, Shiota M, Fukuda S, et al. Strong evidence of a combination polymorphism of the tyrosine kinase 2 gene and the signal transducer and activator of transcription 3 gene as a DNA-based biomarker for susceptibility to Crohn’s disease in the Japanese population. J Clin Immunol. 2009;29(6):815–825.
   PubMed Web of Science ®Google Scholar
• Diaz-Gallo LM, Palomino-Morales RJ, Gómez-García M, et al. STAT4 gene influences genetic predisposition to ulcerative colitis but not Crohn’s disease in the Spanish population: a replication study. Hum Immunol. 2010;71(5):515–519.
   PubMed Web of Science ®Google Scholar
• Globig AM, Hennecke N, Martin B, et al. Comprehensive intestinal T helper cell profiling reveals specific accumulation of IFN-γ+IL-17+coproducing CD4+ T cells in active inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(12):2321–2329.
   PubMed Web of Science ®Google Scholar
• Mencarelli A, Vacca M, Khameneh HJ, et al. Calcineurin B in CD4+ T cells prevents autoimmune colitis by negatively regulating the JAK/STAT pathway. Front Immunol. 2018;9:261.
   PubMed Web of Science ®Google Scholar
• Sakuraba A, Sato T, Kamada N, et al. Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn’s disease. Gastroenterology. 2009;137(5):1736–1745.
   PubMed Web of Science ®Google Scholar
• Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004;113(10):1490–1497.
   PubMed Web of Science ®Google Scholar
• Hovhannisyan Z, Treatman J, Littman DR, et al. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology. 2011;140(3):957–965.
   PubMed Web of Science ®Google Scholar
• Ueno A, Jijon H, Chan R, et al. Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. Inflamm Bowel Dis. 2013;19(12):2522–2534.
   PubMed Web of Science ®Google Scholar
• Eriguchi Y, Nakamura K, Yokoi Y, et al. Essential role of IFN-γ in T cell-associated intestinal inflammation. JCI Insight. 2018;3(18):e121886.
   PubMed Web of Science ®Google Scholar
• Flanagan ME, Blumenkopf TA, Bris- Sette WH, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem. 2010;53(24):8468–8484.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–1736.
   PubMed Web of Science ®Google Scholar
• Hanauer S, Panacciome R, Danese S, et al. Tofacitinb induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17:139–147.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Su C, Lawendy N, et al. Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomized RIVETING trial. J Crohns Colitis. 2021;15(7):1130–1141.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Peyrin-Biroulet L, Quirk D, et al. Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis. Clin Gastroenterol Hepatol. 2022;20(8):1821–1830.e3.
   PubMed Web of Science ®Google Scholar
• Berinstein JA, Steiner CA, Regal RE, et al. Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17(5):988–990.e1.
   PubMed Web of Science ®Google Scholar
• Berinstein JA, Sheehan JL, Dias M, et al. Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study. Clin Gastroenterol Hepatol. 2021;19(10):2112–2120.e1.
   PubMed Web of Science ®Google Scholar
• Kotwani P, Terdiman J, Lewin S. Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience. J Crohns Colitis. 2020;14(7):1026–1028.
   PubMed Web of Science ®Google Scholar
• Gilmore R, Hilley P, Srinivasan A, et al. Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis. J Crohns Colitis. 2022;16(1):166–168.
   PubMed Web of Science ®Google Scholar
• Namour F, Diderichsen PM, Cox E, et al. Pharmacokinetics and pharmaco- kinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015;54(8):859–874.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Danese S, Loftus EV Jr., et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397(10292):2372–2384.
   PubMed Web of Science ®Google Scholar
• Danese S, Ferrante M, Feagan BG, et al. Rapid and sustained symptom relief in patients with ulcerative colitis treated with filgotinib: data from the phase 2b/3 SELECTION trial. Am J Gastroenterol. 2023;118(1):138–147.
   PubMed Web of Science ®Google Scholar
• Loftus EV, Vermeire S, Feagan BG, et al. Corticosteroid-sparing effects of filgotinib in moderate to severely active ulcerative colitis: data from the phase 2b/3 SELECTION study. J Crohns Colitis. 2023;17(2):211–220.
   PubMed Web of Science ®Google Scholar
• Hibi T, Motoya S, Hisamatsu T, et al. Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial. Intest Res. 2023;21(1):110–125.
   PubMedGoogle Scholar
• Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113–2128.
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr., Colombel JF, Takeuchi K, et al. Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment. Clin Gastroenterol Hepatol. 2022. DOI:10.1016/j.cgh.2022.11.029
   Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616–624.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Lawendy N, Danese S, et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther. 2022;55(4):464–478.
   PubMed Web of Science ®Google Scholar
• Din S, Selinger CP, Black CJ, et al. Systematic review with network meta-analysis: risk of herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Aliment Pharmacol Ther. 2023;57(6):666–675.
   PubMed Web of Science ®Google Scholar
• Olivera PA, Lasa JS, Bonovas S, et al. Safety of Janus kinase inhibitors in patients with inflammatory bowel disease or other immune-mediated disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1554–1573.e12.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, D'Haens GR, Sands BE, et al. Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical program. J Crohns Colitis. 2022. DOI:10.1093/ecco-jcc/jjac141.
   Google Scholar
• Stefan Schreiber, DDW 2021: Phase 2b/3 SELECTION and long term extension study results. touchIMMUNOLOGY. Available from: https://www.touchimmunology.com/inflammatory- bowel-disease/conference-hub/stefan-schreiber-ddw-2021-phase-2b-3-selection-and-long-term-extension-study-results/
   Google Scholar
• Hellstrom WJG, Dolhain RJEM, Ritter TE, et al. MANTA and MANTA-RAy: rationale and design of trials evaluating effects of filgotinib on semen parameters in patients with inflammatory diseases. Adv Ther. 2022;39(7):3403–3422.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Panaccione R, Nakase H, et al. The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the phase 3 U-ACHIEVE STUDY is consistent with that in approved indications. Gastroenterology. 2022;162(7):S967–S968.
   Web of Science ®Google Scholar
• Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020;59:481–491.e3.
   Google Scholar
• D’Amico F, Danese S, Peyrin-Biroulet L. Systematic review on inflammatory bowel disease patients with coronavirus disease 2019: it is time to take stock. Clin Gastroenterol Hepatol. 2020;18(12):2689–2700.
   PubMed Web of Science ®Google Scholar
• Seif F, Aazami H, Khoshmirsafa M, et al. JAK inhibition as a new treatment strategy for patients with COVID-19. Int Arch Allergy Immunol. 2020;181(6):467–475.
   PubMed Web of Science ®Google Scholar
• Robinson PC, Richards D, Tanner HL, et al. Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. Lancet Rheumatol. 2020;2(11):e653–e655.
   PubMedGoogle Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med. 2021;384(9):795–807.
   PubMed Web of Science ®Google Scholar
• Westhovens R, Rigby WFC, van der Heijde D, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomized controlled FINCH 3 trial. Ann Rheum Dis. 2021;80(6):727–738.
   PubMed Web of Science ®Google Scholar
• Lasa JS, Olivera PA, Danese S, et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161–170.
   PubMed Web of Science ®Google Scholar
• Choy EH. Clinical significance of Janus kinase inhibitor selectivity. Rheumatology. 2019;58(6):953–962.
   PubMed Web of Science ®Google Scholar